The UGT1A128 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation

European Journal of Cancer

Volumn 46, Issue 11, 2010, Pages 2097-2103

  Liu, Yong ^a   Ramírez, Jacqueline ^a   House, Larry ^a   Ratain, Mark J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Drug drug interactions; Erlotinib; Irinotecan; SN 38 glucuronidation; UGT1A128

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ERLOTINIB; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; 7-ETHYL-10-HYDROXYCAMPTOTHECIN GLUCURONIDE; ANTINEOPLASTIC AGENT; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; CAMPTOTHECIN; DRUG DERIVATIVE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFECT; DRUG GLUCURONIDATION; DRUG INHIBITION; ENZYME INHIBITION; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LIVER MICROSOME; MAJOR CLINICAL STUDY; MALE; PHARMACOKINETICS; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCHOOL CHILD; ADOLESCENT; AGED; DRUG COMBINATION; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHENOTYPE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CAMPTOTHECIN; CHILD; DRUG COMBINATIONS; FEMALE; GENOTYPE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MICROSOMES, LIVER; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; PROTEIN KINASE INHIBITORS; QUINAZOLINES; YOUNG ADULT;

EID: 77954218613     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.04.022     Document Type: Article

References (27)

1. C.S. Fuchs, M.R. Moore, and G. Harker Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer J Clin Oncol 21 2003 807 814
2. F. Innocenti, S.D. Undevia, and L. Iyer Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan J Clin Oncol 22 2004 1382 1388
3. J.M. Hoskins, R.M. Goldberg, P. Qu, J.G. Ibrahim, and H.L. McLeod UGT1A128 genotype and irinotecan-induced neutropenia: dose matters J Natl Cancer Inst 99 2007 1290 1295
4. N. Hanioka, S. Ozawa, and H. Jinno Human liver UDP- glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin Xenobiotica 31 2001 687 699
5. R.P. Ramchandani, Y. Wang, and B.P. Booth The role of SN-38 exposure, UGT1A128 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity J Clin Pharmacol 47 2007 78 86
6. L. Iyer, D. Hall, and S. Das Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism Clin Pharmacol Ther 65 1999 576 582
7. Y. Ando, H. Saka, and G. Asai UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan Ann Oncol 9 1998 845 847
8. L. Iyer, S. Das, and L. Janisch UGT1A128 polymorphism as a determinant of irinotecan disposition and toxicity Pharmacogenomics J 2 2002 43 47
9. Y. Liu, J. Ramirez, L. House, and M.J. Ratain Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases Drug Metab Dispos 38 2010 32 39
10. E.E. Vokes, and E. Chu Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers Oncology (Williston Park) 20 Suppl. 2 2006 15 25
11. D. Cunningham, Y. Humblet, and S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer New Engl J Med 351 2004 337 345
12. A. Arora, and E.M. Scholar Role of tyrosine kinase inhibitors in cancer therapy J Pharmacol Exp Ther 315 2005 971 979
13. J. Chen, M. Smith, and K. Kolinsky Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models Cancer Chemother Pharmacol 59 2007 651 659
14. E. Bajetta, M. Di Bartolomeo, and R. Buzzoni Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients Cancer Chemother Pharmacol 64 2009 67 72
15. W.A. Messersmith, D.A. Laheru, and N.N. Senzer Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities Clin Cancer Res 10 2004 6522 6527
16. L. Iyer, D. Hall, and S. Das Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism Clin Pharmacol Ther 65 1999 576 582
17. W.P. Yong, J. Ramirez, F. Innocenti, and M.J. Ratain Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes Clin Cancer Res 11 2005 6699 6704
18. F. Innocenti, W. Liu, and P. Chen Haplotypes of variants in the UDP-glucuronosyltransferase 1A9 and 1A1 genes Pharmacogenet Genomics 15 2005 295 301
19. R.A. Copeland Enzymes: a practical introduction to structure, mechanism, and data analysis 2000 Wiley-VCH New York
20. P. Frohna, J. Lu, and S. Eppler Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects J Clin Pharmacol 46 2006 282 290
21. N. Yamamoto, A. Horiike, and Y. Fujisaka Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors Cancer Chemother Pharmacol 61 2008 489 496
22. V. Uchaipichat, P.I. Mackenzie, D.J. Elliot, and J.O. Miners Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human UDP-glucuronosyltransferases Drug Metab Dispos 34 2006 449 456
23. L. Luukkanen, J. Taskinen, and M. Kurkela Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases Drug Metab Dispos 33 2005 1017 1026
24. J. Smith Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer Clin Ther 27 2005 1513 1534
25. J. Li, M. Zhao, P. He, M. Hidalgo, and S.D. Baker Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes Clin Cancer Res 13 2007 3731 3737
26. N. Hanioka, S. Ozawa, and H. Jinno Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes Drug Metab Dispos 30 2002 391 396
27. E. Gupta, T.M. Lestingi, and R. Mick Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea Cancer Res 54 1994 3723 3725